Flot.bio x Philip Hemme
Listen now
More Episodes
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and...
Published 10/28/24
We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier. We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was...
Published 10/01/24